Drug Development Pipeline
Back to the Drug Development Pipeline
Inhaled aztreonam (Cayston®) is an antibiotic that has been approved for people with CF who are chronically infected with Pseudomonas aeruginosa.
A Phase 3 clinical trial demonstrated improvement in lung function and respiratory symptoms for those infected with Pseudomonas aeruginosa. Cayston® received FDA approval in 2010.
The program was sponsored by Gilead Sciences, Inc. and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Aztreonam (Cayston®) Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More